Hunan Fangsheng Pharmaceutical Co., Ltd. (SHA:603998)

China flag China · Delayed Price · Currency is CNY
9.58
-0.04 (-0.42%)
Jun 11, 2026, 1:05 PM CST
Market Cap4.22B +0.1%
Revenue (ttm)1.79B +1.9%
Net Income306.52M +12.2%
EPS0.70 +12.9%
Shares Out 439.08M
PE Ratio13.74
Forward PE11.59
Dividend0.45 (4.70%)
Ex-Dividend DateMay 29, 2026
Volume2,135,900
Open9.54
Previous Close9.62
Day's Range9.45 - 9.62
52-Week Range9.39 - 13.50
Beta0.29
AnalystsStrong Buy
Price Target15.32 (+59.92%)
Earnings DateAug 28, 2026

About SHA:603998

Hunan Fangsheng Pharmaceutical Co., Ltd. engages in research, develops, produces, and sells traditional Chinese medicine industry and chemical pharmaceutical products in China. The company offers pharmaceutical manufacturing; and provides cardiovascular and cerebrovascular drugs, skeletal muscle system drugs, orthopedic drugs, respiratory drugs, pediatric drugs, gynecological drugs, and anti-infective drugs. The company's main products include Xuesetong dispersible tablets, Xuesetong tablets, Garcinia bone-strengthening tablets, Dieda Huoxue ca... [Read more]

Sector Healthcare
Founded 2002
Employees 1,868
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 603998
Full Company Profile

Financial Performance

In 2025, SHA:603998's revenue was 1.75 billion, a decrease of -1.75% compared to the previous year's 1.78 billion. Earnings were 306.39 million, an increase of 20.05%.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 603998 stock is "Strong Buy." The 12-month stock price target is ¥15.32, which is an increase of 59.92% from the latest price.

Price Target
¥15.32
(59.92% upside)
Analyst Consensus: Strong Buy
Stock Forecasts